Patents by Inventor Penglie Zhang

Penglie Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Indane-amines as PD-L1 antagonists
    Patent number: 11135210
    Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: January 14, 2020
    Date of Patent: October 5, 2021
    Assignee: ChemoCentryx, Inc.
    Inventors: Christopher Lange, Sreenivas Punna, Rajinder Singh, Ju Yang, Penglie Zhang
  • DEUTERATED COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20210276955
    Abstract: Compounds are provided to modulate the C5a receptor. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: October 9, 2020
    Publication date: September 9, 2021
    Inventors: Pingchen FAN, Rebecca M. LUI, Venkat Reddy MALI, Rajinder SINGH, Yibin ZENG, Penglie ZHANG
  • METHODS OF TREATING CANCER WITH SMALL MOLECULE PD-L1 INHIBITORS
    Publication number: 20210236476
    Abstract: The present disclosure provides, inter alia, methods of treating cancer by administering an effective amount of a com-pound of Formula (I). In some embodiments, the cancer is a solid cancer. In some embodiments, the cancer is melanoma. In some aspects, the present disclosure provides methods of increasing the CD8+ T cell/CD4+ T cell ratio in a solid tumor microenvironment by administering an effective amount of a compound of Formula (I).
    Type: Application
    Filed: August 28, 2019
    Publication date: August 5, 2021
    Inventors: Shijie LI, Marta VILALTA-COLOMER, Sreenivas PUNNA, Viengkham MALATHONG, Rajinder SINGH, Penglie ZHANG
  • Macrocyclic immunomodulators
    Patent number: 11059834
    Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (I) or (II): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R, R1, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, R6c, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: July 8, 2019
    Date of Patent: July 13, 2021
    Assignee: ChemoCentryx, Inc.
    Inventors: Viengkham Malathong, Jeffrey McMahon, Darren J. McMurtrie, Sreenivas Punna, Howard S. Roth, Rajinder Singh, Penglie Zhang
  • CXCR7 antagonists
    Patent number: 11059825
    Abstract: Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: July 13, 2021
    Assignee: ChemoCentryx, Inc.
    Inventors: Junfa Fan, Antoni Krasinski, Christopher W. Lange, Rebecca M. Lui, Jeffrey P. McMahon, Jay P. Powers, Yibin Zeng, Penglie Zhang
  • Inhibitors of CXCR2
    Patent number: 11040960
    Abstract: Compounds are provided as inhibitors of CXCR2, having the structure:
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: June 22, 2021
    Assignee: ChemoCentryx, Inc.
    Inventors: Xi Chen, Dean R. Dragoli, Junfa Fan, Jaroslaw Kalisiak, Manmohan Reddy Leleti, Viengkham Malathong, Jeffrey McMahon, Hiroko Tanaka, Ju Yang, Chao Yu, Penglie Zhang, Venkat Mali
  • Free base crystalline form of a complement component C5a receptor
    Patent number: 11026935
    Abstract: Provided herein is a free base crystalline form of a complement component 5a receptor having the formula of Compound 1 Also provided herein are pharmaceutical compositions and methods of treatment using the crystalline free base form of Compound 1 described herein.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: June 8, 2021
    Assignee: ChemoCentryx, Inc.
    Inventors: Rajinder Singh, Kwok Yau, Yibin Zeng, Penglie Zhang, Rebecca M. Lui, Antoni Krasinski
  • Compositions and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of C—C chemokine receptor type 9 (CCR9) and anti-?4?7 integrin blocking antibodies
    Patent number: 11020394
    Abstract: Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-?4?7 integrin antibody such as vedolizumab. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-?4?7 integrin antibody.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: June 1, 2021
    Assignee: ChemoCentryx, Inc.
    Inventors: Yibin Zeng, Penglie Zhang, Thomas Schall, Israel Charo, James J. Campbell
  • IMMUNOMODULATOR COMPOUNDS
    Publication number: 20210147356
    Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein Z, L, R1a, R1b, R1c, R1d, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: November 30, 2020
    Publication date: May 20, 2021
    Inventors: Christopher LANGE, Viengkham MALATHONG, Venkat Reddy MALI, Jeffrey McMAHON, Darren J. McMURTRIE, Sreenivas PUNNA, Howard S. ROTH, Rajinder SINGH, Yu WANG, Ju YANG, Penglie ZHANG
  • FREE BASE CRYSTALLINE FORM OF A COMPLEMENT COMPONENT C5a RECEPTOR
    Publication number: 20210137907
    Abstract: Provided herein is a free base crystalline form of a complement component 5a receptor having the formula of Compound 1 Also provided herein are pharmaceutical compositions and methods of treatment using the crystalline free base form of Compound 1 described herein.
    Type: Application
    Filed: November 6, 2020
    Publication date: May 13, 2021
    Inventors: Rajinder SINGH, Kwok YAU, Yibin ZENG, Penglie ZHANG, Rebecca M. LUI, Antoni KRASINSKI
  • SALT FORMS OF A COMPLEMENT COMPONENT C5A RECEPTOR
    Publication number: 20210139427
    Abstract: Provided herein are salt forms of a complement component 5a receptor having the formula of Compound 1 Also provided herein are pharmaceutical compositions and methods of treatment using the salt forms of Compound 1, described herein.
    Type: Application
    Filed: November 6, 2020
    Publication date: May 13, 2021
    Inventors: Rajinder SINGH, Kwok YAU, Yibin ZENG, Penglie ZHANG, Rebecca M. LUI, Ju YANG, Howard S. ROTH
  • AMORPHOUS FORM OF A COMPLEMENT COMPONENT C5a RECEPTOR
    Publication number: 20210139426
    Abstract: Provided herein is an amorphous form of a complement component 5a receptor having the formula of Compound 1 Also provided herein are pharmaceutical compositions and methods of treatment using the amorphous form of Compound 1, described herein.
    Type: Application
    Filed: November 6, 2020
    Publication date: May 13, 2021
    Inventors: Kwok YAU, Kenken LUONG, Rajinder SINGH, Yibin ZENG, Penglie ZHANG, Manmohan Reddy LELETI, Rebecca M. LUI
  • HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES
    Publication number: 20210130347
    Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R2a, R2b, R3, R3a, R4, R6, R7, R8, A, Z, X1 and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: October 15, 2020
    Publication date: May 6, 2021
    Inventors: Pingchen FAN, Christopher W. LANGE, Rebecca M. LUI, Darren J. McMURTRIE, Ryan J. SCAMP, Ju YANG, Yibin ZENG, Penglie ZHANG
  • HETEROARYL-BIPHENYL AMIDES FOR THE TREATMENT OF PD-L1 DISEASES
    Publication number: 20210130325
    Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R2a, R2b, R3, R3a, R4, R6, R7, R8, A, Z, X1 and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: October 15, 2020
    Publication date: May 6, 2021
    Inventors: Pingchen FAN, Christopher W. LANGE, Rebecca M. LUI, Darren J. McMURTRIE, Ryan J. SCAMP, Ju YANG, Yibin ZENG, Penglie ZHANG
  • Modulators of chemokine receptors
    Patent number: 10988464
    Abstract: Compounds are provided as chemokine inhibitors having the structure:
    Type: Grant
    Filed: May 16, 2019
    Date of Patent: April 27, 2021
    Assignee: ChemoCentryx, Inc.
    Inventors: Xi Chen, Dean R. Dragoli, Junfa Fan, Jaroslaw Kalisiak, Antoni Krasinski, Manmohan Reddy Leleti, Venkat Mali, Jeffrey McMahon, Rajinder Singh, Hiroko Tanaka, Ju Yang, Chao Yu, Penglie Zhang
  • DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS
    Publication number: 20210106568
    Abstract: The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.
    Type: Application
    Filed: September 25, 2020
    Publication date: April 15, 2021
    Inventors: Pingchen FAN, Christopher W. LANGE, Viengkham MALATHONG, Venkat Reddy MALI, Sreenivas PUNNA, Hiroko TANAKA, Yibin ZENG, Penglie ZHANG
  • 2-OXINDOLE COMPOUNDS
    Publication number: 20210101890
    Abstract: Oxindole compounds useful for the treatment of CCR(9) mediated conditions or diseases are provided.
    Type: Application
    Filed: July 17, 2020
    Publication date: April 8, 2021
    Inventors: Xi CHEN, Dean R. DRAGOLI, Pingchen FAN, Manmohan Reddy LELETI, Rebecca M. LUI, Viengkham MALATHONG, Jay P. POWERS, Rajinder SINGH, Hiroko TANAKA, Ju YANG, Chao YU, Penglie ZHANG
  • DIAZOLE LACTAMS
    Publication number: 20210093613
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are diazole lactam derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Application
    Filed: July 8, 2020
    Publication date: April 1, 2021
    Inventors: Xi CHEN, Pingchen FAN, Yandong LI, Jay P. POWERS, Viengkham MALATHONG, Sreenivas PUNNA, Hiroko TANAKA, Penglie ZHANG, Dean DRAGOLI
  • IMMUNOMODULATOR COMPOUNDS
    Publication number: 20210052514
    Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (II): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: January 23, 2020
    Publication date: February 25, 2021
    Inventors: Christopher LANGE, Viengkham MALATHONG, Darren J. McMURTRIE, Sreenivas PUNNA, Rajinder SINGH, Ju YANG, Penglie ZHANG
  • PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS
    Publication number: 20210052612
    Abstract: The present disclosure provides, inter alia, Compounds of Formulae IA, IB, IC, IIA, IIB and IIC or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.
    Type: Application
    Filed: April 1, 2019
    Publication date: February 25, 2021
    Inventors: Pingchen FAN, Rebecca M. LUI, Rajinder SINGH, Venkat Reddy MALI, Yibin ZENG, Penglie ZHANG